TrialJournal of hematology & oncology2024

Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study.

Jianliang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.